These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36154176)

  • 1. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
    Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
    Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One
    Wainwright C; McColley SA; McNally P; Powers M; Ratjen F; Rayment JH; Retsch-Bogart G; Roesch E; Ahluwalia N; Chin A; Chu C; Lu M; Menon P; Waltz D; Weinstock T; Zelazoski L; Davies JC
    Am J Respir Crit Care Med; 2023 Jul; 208(1):68-78. PubMed ID: 37154609
    [No Abstract]   [Full Text] [Related]  

  • 4. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
    Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
    [No Abstract]   [Full Text] [Related]  

  • 6. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
    Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA
    Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
    Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
    Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
    Lopez A; Daly C; Vega-Hernandez G; MacGregor G; Rubin JL
    J Cyst Fibros; 2023 Jul; 22(4):607-614. PubMed ID: 36849331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
    Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
    Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 11. EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS.
    Lee T; Sawicki GS; Altenburg J; Millar SJ; Geiger JM; Jennings MT; Lou Y; McGarry LJ; Van Brunt K; Linnemann RW
    J Cyst Fibros; 2023 May; 22(3):402-406. PubMed ID: 36581485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
    Bower JK; Volkova N; Ahluwalia N; Sahota G; Xuan F; Chin A; Weinstock TG; Ostrenga J; Elbert A
    J Cyst Fibros; 2023 Jul; 22(4):730-737. PubMed ID: 36963986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
    Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
    J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One
    Goralski JL; Hoppe JE; Mall MA; McColley SA; McKone E; Ramsey B; Rayment JH; Robinson P; Stehling F; Taylor-Cousar JL; Tullis E; Ahluwalia N; Chin A; Chu C; Lu M; Niu T; Weinstock T; Ratjen F; Rosenfeld M
    Am J Respir Crit Care Med; 2023 Jul; 208(1):59-67. PubMed ID: 36921081
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
    McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
    J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
    Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
    Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
    Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
    J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
    Ramsey B; Correll CU; DeMaso DR; McKone E; Tullis E; Taylor-Cousar JL; Chu C; Volkova N; Ahluwalia N; Waltz D; Tian S; Mall MA
    Am J Respir Crit Care Med; 2024 Feb; 209(3):299-306. PubMed ID: 37890129
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
    Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
    Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.